GlassScriptPhysician profile
Terrence John Norton
NPI 1336207588
$19,562.10
in general payments reported to CMS, 2019-2025
26 companies · $8,987 in 2025
The $8,987 reported for 2025 was more than what 95% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,758 · 2020: $208 · 2021: $125 · 2022: $390 · 2023: $475 · 2024: $619 · 2025: $8,987.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,470 · Food and Beverage: $2,175 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,910 · Travel and Lodging: $519 · Education: $6.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,470.00 |
| Food and Beverage | $2,174.57 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,910.00 |
| Travel and Lodging | $519.26 |
| Education | $6.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $8,436.41 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Avanir Pharmaceuticals, INC. | $8,205.70 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $340.60 | 2019-2025 | Trintellix |
| Abbvie INC. | $329.77 | 2022-2025 | |
| Lundbeck LLC | $328.72 | 2019-2025 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $295.72 | 2019-2025 | Abilify Asimtufii, Nuedexta, Abilify Maintena |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| Janssen Pharmaceuticals, INC | $187.88 | 2019-2025 | Spravato, Invega Sustenna |
| Allergan, INC. | $160.10 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $156.24 | 2019-2025 | Austedo Xr, Uzedy |
| Corium, LLC | $137.77 | 2022-2024 | Azstarys, Adlarity |
| Vanda Pharmaceuticals INC. | $120.87 | 2019-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $113.08 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $100.09 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $79.72 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $73.38 | 2024-2025 | Cobenfy |
| Acadia Pharmaceuticals INC | $49.81 | 2019-2022 | |
| Sage Therapeutics, LLC | $48.15 | 2024-2025 | Zurzuvae |
| Shire North American Group INC | $46.10 | 2019 | |
| Sunovion Pharmaceuticals INC. | $33.71 | 2019 | |
| Lilly USA, LLC | $30.40 | 2024-2025 | Amyvid, Kisunla |
| Collegium Pharmaceutical, INC. | $23.35 | 2025 | Jornay Pm |
| Axsome Therapeutics, INC. | $18.90 | 2023 | Auvelity |
| Neuronetics, INC. | $17.38 | 2020 | |
| Pfizer INC. | $16.16 | 2025 | |
| Merck Sharp & Dohme LLC | $12.09 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terrence Norton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.